Podoplanin (PDPN) is a type I transmembrane O-glycoprotein, which is known as a specific lymphatic marker. PDPN activates platelet aggregation by binding to C-type lectin-like receptor-2 (CLEC-2) on platelet. PDPN is also expressed in several normal tissues, including podocytes and type I alveolar cells. Although many monoclonal antibodies (MAbs) against human PDPN (hPDPN), mouse PDPN (mPDPN), and rat PDPN (rPDPN) have been established, useful antibodies against rabbit PDPN (rabPDPN) have not been developed. In this study, we immunized mice with the recombinant proteins of rabPDPN, and developed a novel anti-rabPDPN MAb, named PMab-32. PMab-32 could detect endogenous and exogenous rabPDPN in flow cytometry and Western blot analysis. The KD of PMab-32 was determined to be 6.2 × 10−8 M by flow cytometry. Immunohistochemical analysis showed that PMab-32 is useful for detecting podocytes, type I alveolar cells, and lymphatic endothelial cells in normal rabbit tissues. PMab-32 is expected to be useful for various rabbit experiments.
Get full access to this article
View all access options for this article.
References
1.
WetterwaldA, HoffstetterW, CecchiniMG, LanskeB, WagnerC, FleischH, and AtkinsonM: Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone, 1996; 18:125–132.
2.
Breiteneder-GeleffS, MatsuiK, SoleimanA, MeranerP, PoczewskiH, KaltR, SchaffnerG, and KerjaschkiD: Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol, 1997; 151:1141–1152.
3.
Breiteneder-GeleffS, SoleimanA, KowalskiH, HorvatR, AmannG, KriehuberE, DiemK, WeningerW, TschachlerE, AlitaloK, and KerjaschkiD: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol, 1999; 154:385–394.
4.
KanekoMK, KatoY, KitanoT, and OsawaM: Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene, 2006; 378:52–57.
5.
AriizumiT, OgoseA, KawashimaH, HottaT, LiG, XuY, UmezuH, SugaiM, and EndoN: Expression of podoplanin in human bone and bone tumors: new marker of osteogenic and chondrogenic bone tumors. Pathol Int, 2010; 60:193–202.
6.
KatoY, KanekoMK, KunitaA, ItoH, KameyamaA, OgasawaraS, MatsuuraN, HasegawaY, Suzuki-InoueK, InoueO, OzakiY, and NarimatsuH: Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci, 2008; 99:54–61.
7.
KanekoMK, KunitaA, AbeS, TsujimotoY, FukayamaM, GotoK, SawaY, NishiokaY, and KatoY: Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. Cancer Sci, 2012; 103:1913–1919.
8.
NagaeM, Morita-MatsumotoK, KatoM, KanekoMK, KatoY, and YamaguchiY: A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin. Structure, 2014; 22:1711–1721.
PetersA, PitcherLA, SullivanJM, MitsdoerfferM, ActonSE, FranzB, WucherpfennigK, TurleyS, CarrollMC, SobelRA, BettelliE, and KuchrooVK: Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity, 2011; 35:986–996.
12.
AstaritaJL, CremascoV, FuJ, DarnellMC, PeckJR, Nieves-BonillaJM, SongK, KondoY, WoodruffMC, GogineniA, OnderL, LudewigB, WeimerRM, CarrollMC, MooneyDJ, XiaL, and TurleySJ: The CLEC-2-podoplanin axis controls the contractility of fibroblastic reticular cells and lymph node microarchitecture. Nat Immunol, 2015; 16:75–84.
13.
ActonSE, FarrugiaAJ, AstaritaJL, Mourao-SaD, JenkinsRP, NyeE, HooperS, van BlijswijkJ, RogersNC, SnelgroveKJ, RosewellI, MoitaLF, StampG, TurleySJ, SahaiE, and Reis e SousaC: Dendritic cells control fibroblastic reticular network tension and lymph node expansion. Nature, 2014; 514:498–502.
14.
MishimaK, KatoY, KanekoMK, NishikawaR, HiroseT, and MatsutaniM: Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol (Berl), 2006; 111:483–488.
15.
MishimaK, KatoY, KanekoMK, NakazawaY, KunitaA, FujitaN, TsuruoT, NishikawaR, HiroseT, and MatsutaniM: Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathol (Berl), 2006; 111:563–568.
16.
KatoY, VaidyanathanG, KanekoMK, MishimaK, SrivastavaN, ChandramohanV, PegramC, KeirST, KuanCT, BignerDD, and ZalutskyMR: Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl Med Biol, 2010; 37:785–794.
17.
KatoY, and KanekoMK: A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep, 2014; 4:5924.
18.
Ochoa-AlvarezJA, KrishnanH, PastorinoJG, NevelE, KephartD, LeeJJ, RetzbachEP, ShenY, FatahzadehM, BaredesS, KalyoussefE, HonmaM, AdelsonME, KanekoMK, KatoY, YoungMA, Deluca-RaponeL, ShienbaumAJ, YinK, JensenLD, and GoldbergGS: Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms. Oncotarget, 2015; 6:9045–9060.
19.
KatoY, KanekoM, SataM, FujitaN, TsuruoT, and OsawaM: Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumor Biol, 2005; 26:195–200.
20.
SchoppmannSF, JeschB, RieglerMF, MaroskeF, SchwameisK, JomrichG, and BirnerP: Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus. Clin Exp Metastasis, 2013; 30:441–446.
21.
KimuraN, and KimuraI: Podoplanin as a marker for mesothelioma. Pathol Int, 2005; 55:83–86.
22.
AbeS, MoritaY, KanekoMK, HanibuchiM, TsujimotoY, GotoH, KakiuchiS, AonoY, HuangJ, SatoS, KishukuM, TaniguchiY, AzumaM, KawazoeK, SekidoY, YanoS, AkiyamaS, SoneS, MinakuchiK, KatoY, and NishiokaY: A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol, 2013; 190:6239–6249.
23.
KatoY, SasagawaI, KanekoM, OsawaM, FujitaN, and TsuruoT: Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene, 2004; 23:8552–8556.
KunitaA, KashimaTG, OhazamaA, GrigoriadisAE, and FukayamaM: Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma. Am J Pathol, 2011; 179:1041–1049.
26.
KunitaA, KashimaTG, MorishitaY, FukayamaM, KatoY, TsuruoT, and FujitaN: The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol, 2007; 170:1337–1347.
27.
KawaseA, IshiiG, NagaiK, ItoT, NaganoT, MurataY, HishidaT, NishimuraM, YoshidaJ, SuzukiK, and OchiaiA: Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer, 2008; 123:1053–1059.
28.
FujiiY, KanekoM, NeyazakiM, NogiT, KatoY, and TakagiJ: PA tag: a versatile protein tagging system using a super high affinity antibody against a dodecapeptide derived from human podoplanin. Protein Expr Purif, 2014; 95:240–247.
29.
SteinRA, WilkinsonJC, GuyerCA, and StarosJV: An analytical approach to the measurement of equilibrium binding constants: application to EGF binding to EGF receptors in intact cells measured by flow cytometry. Biochemistry, 2001; 40:6142–6154.
30.
KatoY, KunitaA, AbeS, OgasawaraS, FujiiY, OkiH, FukayamaM, NishiokaY, and KanekoMK: The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity. Oncotarget, 2015;DOI: 10.18632/oncotarget.5339.
31.
OkiH, KanekoMK, OgasawaraS, TsujimotoY, LiuX, SugawaraM, TakakuboY, TakagiM, and KatoY: Characterization of a monoclonal antibody LpMab-7 recognizing non-PLAG domain of podoplanin. Monoclon Antib Immunodiagn Immunother, 2015; 34:174–180.
32.
KajiC, TsujimotoY, Kato KanekoM, KatoY, and SawaY: Immunohistochemical examination of novel rat monoclonal antibodies against mouse and human podoplanin. Acta Histochem Cytochem, 2012; 45:227–237.
33.
MaruyamaY, MaruyamaK, KatoY, KajiyaK, MoritohS, YamamotoK, MatsumotoY, SawaneM, KerjaschkiD, NakazawaT, and KinoshitaS: The effect of podoplanin inhibition on lymphangiogenesis under pathological conditions. Invest Ophthalmol Vis Sci, 2014; 55:4813–4822.
34.
OkiH, HonmaR, OgasawaraS, FujiiY, LiuX, KanekoMK, TakagiM, and KatoY: Development of a sensitive monoclonal antibody PMab-2 against rat podoplanin. Monoclon Antib Immunodiagn Immunother, 2015; 34:396–403.
35.
SmithSM, and MelroseJ: Podoplanin is expressed by a sub-population of human foetal rib and knee joint rudiment chondrocytes. Tissue Cell, 2011; 43:39–44.
36.
AkasakiY, MatsudaS, NakayamaK, FukagawaS, MiuraH, and IwamotoY: Mevastatin reduces cartilage degradation in rabbit experimental osteoarthritis through inhibition of synovial inflammation. Osteoarthritis Cartilage, 2009; 17:235–243.
37.
StevensMM, MariniRP, SchaeferD, AronsonJ, LangerR, and ShastriVP: In vivo engineering of organs: the bone bioreactor. Proc Natl Acad Sci USA, 2005; 102:11450–11455.
38.
MuraliS, RaiB, DombrowskiC, LeeJL, LimZX, BramonoDS, LingL, BellT, HinkleyS, NathanSS, HuiJH, WongHK, NurcombeV, and CoolSM: Affinity-selected heparan sulfate for bone repair. Biomaterials, 2013; 34:5594–5605.
39.
PulkkinenHJ, TiituV, ValonenP, JurvelinJS, RieppoL, ToyrasJ, SilvastTS, LammiMJ, and KivirantaI: Repair of osteochondral defects with recombinant human type II collagen gel and autologous chondrocytes in rabbit. Osteoarthritis Cartilage, 2013; 21:481–490.
40.
LyonR, LiuXC, KubinM, and SchwabJ: Does extracorporeal shock wave therapy enhance healing of osteochondritis dissecans of the rabbit knee?: a pilot study. Clin Orthop Relat Res, 2013; 471:1159–1165.
41.
KatoY, KanekoMK, KunoA, UchiyamaN, AmanoK, ChibaY, HasegawaY, HirabayashiJ, NarimatsuH, MishimaK, and OsawaM: Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun, 2006; 349:1301–1307.
42.
OgasawaraS, OkiH, KanekoMK, HozumiY, LiuX, HonmaR, FujiiY, NakamuraT, GotoK, TakagiM, and KatoY: Development of a monoclonal antibody LpMab-10 recognizing non-glycosylated PLAG1/2 domain including Thr34 of human podoplanin. Monoclon Antib Immunodiagn Immunother, 2015; 34:318–326.
43.
KanekoMK, OkiH, HozumiY, LiuX, OgasawaraS, TakagiM, GotoK, and KatoY: A monoclonal antibody LpMab-9 recognizes O-glycosylated N-terminus of human podoplanin. Monoclon Antib Immunodiagn Immunother, 2015; 34:310–317
44.
OkiH, OgasawaraS, KanekoMK, TakagiM, YamauchiM, and KatoY: Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin. Monoclon Antib Immunodiagn Immunother, 2015; 34:44–50.
45.
OgasawaraS, KanekoMK, PriceJE, and KatoY: Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma, 2008; 27:259–267.
46.
KanekoM, KatoY, KunitaA, FujitaN, TsuruoT, and OsawaM: Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/podoplanin) molecules expressed in Chinese hamster ovary cells. J Biol Chem, 2004; 279:38838–38843.
